GLP-1 receptor agonists may be superior to aspirin for primary prevention of colorectal cancer, according to study results presented at ASCO Gastrointestinal Cancers Symposium.
A retrospective analysis of more than 281,000 people showed those who used GLP-1s exhibited a 36% reduced risk for colorectal cancer compared with those who used aspirin. The benefit with GLP-1s appeared even greater among individuals at highest risk due to family history, genetic predisposition or other high-risk comorbidities, such as Crohn’s disease or ulcerative colitis.